On April 22nd, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced that the Company are launching a microbiome test for the Consumer Health (D2C) market in China in collaboration with Thalys Medical Technology Group Corporation (“Thalys”). The test is based on GA’s clinically validated microbiome test, the GA-map® Dysbiosis Test, but specifically adapted to suit the Chinese market, with additional tests expected to be launched by Thalys based on the Genetic Analysis platform in the future.

Länk till analysen